GILD Stock Recent News
GILD LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ:GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning possible violations of federal securities laws. Gilead issued a press release on June 10, 2025, announcing that "[t]he U.S. Food and Drug Administration has placed a clinical hold on Gilead's HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor)[,]" specifying that "[t]he clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ:GILD). Investors who purchased Gilead securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GILD.
Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and upcoming lenacapavir-PrEP launch underpin multi-year growth, with consensus underestimating embedded volume and margin expansion optionality. Disciplined SG&A cuts and high operating leverage enable sustainable margin accretion and above-Street EPS growth, supporting a premium 21x forward P/E multiple.